SOURCE: Galapagos NV

March 14, 2008 13:15 ET

Galapagos ADR listing operational; CEO presents at Cowen Health Care Conference in the U.S.

MECHELEN, BELGIUM--(Marketwire - March 14, 2008) - Galapagos NV (Euronext: GLPG; OTC: GLPYY) announces that its Level 1 American Depositary Receipt (ADR) facility in the United States went operational on 13 March 2008. Furthermore, its Chief Executive Officer, Onno van de Stolpe, will present at the Cowen and Company 28th Annual Health Care Conference in Boston on 20 March 2008.

Mr. Van de Stolpe's presentation will be at 10:15 AM U.S. Eastern time (15.15 CET) on Thursday, March 20th. The live webcast of the presentation can be accessed via Galapagos' website at www.glpg.com. The archived webcast will also be available for replay.

About ADRs ADRs (American Depositary Receipts) enable US investors to acquire and trade non-US securities denominated in US dollars without concern for the different settlement timetables and the problems typically associated with overseas markets. A routine process for most banks, ADRs are created when a US broker purchases a company's ordinary shares on the home stock market and delivers those underlying shares to the depositary's local custodian bank, which then instructs the US depositary bank, in this case, The Bank of New York, to issue ADRs. Level I ADRs are traded in the U.S. Over The Counter (OTC) market with prices published in the "Pink Sheets" and on some exchanges outside the United States. More information on ADRs is available at www.adrbny.com.

About Galapagos Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical programs in bone and joint diseases and bone metastasis. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds. Galapagos currently employs 450 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpg.com and www.biofocusdpi.com.


CONTACTS

Galapagos NV Onno van de Stolpe, CEO Tel: +31 6 2909 8028 ir@glpg.com


This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Nothing in this disclaimer is intended to nor does it affect the obligations and responsibilities of Galapagos pursuant to the rules of the exchanges on which Galapagos' shares are admitted for trading, including the AIM Rules for Companies.





Copyright © Hugin AS 2008. All rights reserved.

Contact Information